A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
This study evaluated the pharmacokinetics, motor effects, and assessed the safety of IPX066
compared with an immediate-release cabridopa-levodopa formulation in subjects with advanced
Parkinson's disease.
Phase:
Phase 2
Details
Lead Sponsor:
IMPAX Laboratories, Inc. Impax Laboratories, LLC
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa